(0) items in cart / view cart / checkout  
 
  Chemicals
  Company Profiles
  Country Analyses
  Energy and Utilities
  Food & Beverage
  In Vitro Diagnostics
  Medical Devices
  Pharmaceuticals & Biotechnology
 
 
  Advertising
Aerospace, Defense
Automotive
Banking
Biotechnology
Business Services
Chemicals
Company Reports
Construction
Consumer Goods
Countries
Diagnostics
Energy, Environment
Food & Beverages
Government
Healthcare
IT
Manufacturing
Media
Medical Devices
Pharmaceuticals
Retailing
Sales & Marketing
Sourcing
Telecommunications
Transportation
Travel, Entertainment
 
Home > In Vitro Diagnostics Molecular Diagnostics >  2021-2025 U.K. Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing Markets: Country Forecasts, Emerging Technologies, Competitive Strategies

2021-2025 U.K. Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing Markets: Country Forecasts, Emerging Technologies, Competitive Strategies




Complete report $1,850.  DataPack (test volumes, sales forecasts, supplier shares) $1,200.  The report is available by section, market segment, and can be custom-tailored to your specific information needs and budget. 

This new study from Venture Planning Group contains 408 pages, and is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities for molecular diagnostic technologies and products in testing for genetic diseases, cancer, as well as forensic and paternity/HLA typing applications during the next five years. 

Report Highlights

- Market shares of leading suppliers
- Business and technological trends in major markets
- Five-year test volume and sales forecasts
- Market shares of leading competitors
- Feature comparison of major analyzers
- Strategic profiles of leading market players and start-up firms developing innovative products
- Specific product and business opportunities for instrument and consumable suppliers.

Rationale

Genetic Diseases, Cancer, Forensic and Paternity molecular diagnostic testing markets are among the most rapidly growing segments of the in vitro diagnostics industry.  The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches.  The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods.  In order to successfully capitalize on the opportunities presented by these markets, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies.  Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.

U.K. Market Overview

- Laboratories performing DNA sequencing and molecular diagnostic testing by country and market segment.

- Five-year test volume and sales projections.

Market Segmentation Analysis

- Five-year test volume and sales projections:

- Infectious Diseases        - Forensic Testing
- Cancer                            - Paternity Testing/HLA Typing
- Genetic Diseases            - Others

- A comprehensive analysis of the sequencing market by laboratory segment.
  
- Detailed market segmentation analysis, including review of the market dynamics, trends,
  structure, size, growth and major suppliers.

Product/Technology Review

- Comparison of the major molecular diagnostic analyzers.

- Extensive review of molecular diagnostic technologies, test formats, detection methodologies,
  trends in testing automation and over target/signal amplification methods.

- Worldwide listings of companies, universities and research centers developing new molecular
   diagnostic technologies and products.

Competitive Assessments

- Extensive strategic assessments of major suppliers and emerging market entrants,
  including their sales, product portfolios, marketing tactics, collaborative arrangements and
  new technologies/products in R&D.
  
   - Abbott
   - Affymetrix
   - Agilent Technologies
   - Applied Gene Technologies
   - Arca/Nuvelo
   - Beckman Coulter/Danaher
   - Becton Dickinson
   - Biokit
   - BioMerieux
   - Bio-Rad
   - Biotest
   - Caliper
   - Cepheid
   - Decode
   - Diadexus
   - Eiken
   - Enzo
   - Exact Sciences
   - Fujirebio/Innogenetics
   - Grifols
   - Hologic/Gen-Probe
   - Illumina
   - Kreatech
   - Li-Cor Biosciences
   - Life Technologies/Thermo Fisher
   - Monogram Biosciences
   - Myriad Genetics
   - Nanogen/Elitech
   - Orchid CellMark
   - Ortho-Clinical Diagnostics
   - Proteome Sciences
   - Qiagen              
   - Roche
   - Scienion
   - Sequenom
   - Shimadzu
   - Siemens
   - Sierra Molecular
   - Takara Bio
   - Tecan Group

- Comprehensive listings of companies developing and marketing molecular
  diagnostic products, by test and application.

Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal
  during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

- Business planning issues and concerns.

Contains 408 pages



To order sections of this report, contact Client Services


     
   
Local PDF: $1850.00
Other Formats: Global PDF, DataPack
   
   
 
VPGMarketResearch.com © Copyright 2015. all rights reserved. Web Design by Spida Design  
  Close  X